Arcellx Inc (ACLX)

$115.05 -0.05 (-0.04%)
Market Cap 6.73B
Revenue (ttm) 22.29M
Net Income (ttm) -228.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,027.05%
Debt to Equity Ratio 0.00
Volume 479,500
Avg Vol 2,485,322
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 80%
Beta 0.25
Analysts Sell
Price Target $104.15

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
TwongStocks
TwongStocks Apr. 17 at 12:32 PM
$GILD Gilead Receives All Required Regulatory Approvals for the Acquisition of $ACLX Arcellx and Extends Tender Offer https://www.businesswire.com/news/home/20260417916113/en/Gilead-Receives-All-Required-Regulatory-Approvals-for-the-Acquisition-of-Arcellx-and-Extends-Tender-Offer "The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions. "
0 · Reply
RobinCollins1
RobinCollins1 Apr. 2 at 8:14 AM
$GILD keeps the pressure on—extending its tender offer for $ACLX to April 24 So far only ~7.5% of shares tendered, which signals: • Limited early acceptance • Potential resistance from holders • The deal still needs momentum to move forward For $GILD, this extension is a strategic move—buy more time to secure a higher acceptance rate without raising the offer (at least for now). For $ACLX holders, the low tender rate keeps the deal in a bit of a “wait-and-see” zone. If participation stays low, expect: Continued deal pressure Possible negotiation dynamics Increased volatility into the deadline
0 · Reply
DonCorleone77
DonCorleone77 Apr. 1 at 8:16 PM
$ACLX $GILD Gilead extends tender offer to acquire Arcellx Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
0 · Reply
SBroomy
SBroomy Mar. 19 at 2:06 PM
$ACLX $SPY Unfazed by whatever is going on in the market
0 · Reply
Innovatenow
Innovatenow Mar. 7 at 5:11 AM
$ACLX https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-is-investigating-the-mergeraclx-vre-ehab-and-ceco-302704159.html
0 · Reply
Mergerbrief
Mergerbrief Mar. 6 at 12:38 PM
$ACLX / $GILD – Tender Offer File By date
0 · Reply
SBroomy
SBroomy Mar. 5 at 6:36 PM
$ACLX $SPY Arcellx have hold up very well since it's gains.
0 · Reply
Achandler787
Achandler787 Mar. 5 at 3:56 AM
$ACLX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 6:59 PM
$ACLX RSI: 85.61, MACD: 11.9080 Vol: 21.44, MA20: 81.95, MA50: 72.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 27 at 2:20 AM
$ACLX congrats longs! $GILD should buy $ALT or $IMRX next 🚀
0 · Reply
Latest News on ACLX
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Mar 19, 2026, 8:00 AM EDT - 4 weeks ago

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

KW

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Mar 18, 2026, 8:59 AM EDT - 4 weeks ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

AVIR

Top 2 Health Care Stocks That May Crash This Quarter

Mar 4, 2026, 8:55 AM EST - 6 weeks ago

Top 2 Health Care Stocks That May Crash This Quarter

ANIK

Here's Why Shares of Arcellx Are Up Almost 80% Today

Feb 23, 2026, 2:25 PM EST - 7 weeks ago

Here's Why Shares of Arcellx Are Up Almost 80% Today

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

Feb 23, 2026, 8:41 AM EST - 7 weeks ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

GILD

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Feb 23, 2026, 7:52 AM EST - 7 weeks ago

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

GILD

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Feb 23, 2026, 6:36 AM EST - 7 weeks ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

GILD

Gilead to acquire Arcellx for $7.8 billion

Feb 23, 2026, 6:08 AM EST - 7 weeks ago

Gilead to acquire Arcellx for $7.8 billion

GILD

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 7 weeks ago

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

GILD

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 7 weeks ago

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

GILD

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

Feb 4, 2026, 9:00 AM EST - 2 months ago

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Jan 21, 2026, 4:00 PM EST - 3 months ago

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 4 months ago

Cancer Study Buoys These Small Biotechs

LEGN TERN

Why Is Arcellx Stock Surging Today?

Dec 8, 2025, 1:23 PM EST - 4 months ago

Why Is Arcellx Stock Surging Today?

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Dec 6, 2025, 2:00 PM EST - 4 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Nov 18, 2025, 4:00 PM EST - 5 months ago

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 5 months ago

Arcellx Provides Third Quarter 2025 Financial Results

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:00 AM EST - 5 months ago

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Sep 3, 2025, 4:00 PM EDT - 8 months ago

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:00 PM EDT - 9 months ago

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025, 4:00 PM EDT - 11 months ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 18, 2025, 8:44 AM EDT - 1 year ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Dec 9, 2024, 7:50 AM EST - 1 year ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Dec 8, 2024, 11:00 PM EST - 1 year ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 2 years ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 2 years ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter 2024 Financial Results

Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 20, 2024, 4:00 PM EDT - 2 years ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 4:00 PM EST - 2 years ago

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Feb 28, 2024, 4:00 PM EST - 2 years ago

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Dec 8, 2023, 4:00 PM EST - 2 years ago

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

Nov 15, 2023, 6:23 AM EST - 2 years ago

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

GILD

Kite and Arcellx Announce Expansion in Strategic Partnership

Nov 15, 2023, 6:00 AM EST - 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Nov 15, 2023, 6:00 AM EST - 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 4:00 PM EST - 2 years ago

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Aug 14, 2023, 4:00 PM EDT - 2 years ago

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

TwongStocks
TwongStocks Apr. 17 at 12:32 PM
$GILD Gilead Receives All Required Regulatory Approvals for the Acquisition of $ACLX Arcellx and Extends Tender Offer https://www.businesswire.com/news/home/20260417916113/en/Gilead-Receives-All-Required-Regulatory-Approvals-for-the-Acquisition-of-Arcellx-and-Extends-Tender-Offer "The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions. "
0 · Reply
RobinCollins1
RobinCollins1 Apr. 2 at 8:14 AM
$GILD keeps the pressure on—extending its tender offer for $ACLX to April 24 So far only ~7.5% of shares tendered, which signals: • Limited early acceptance • Potential resistance from holders • The deal still needs momentum to move forward For $GILD, this extension is a strategic move—buy more time to secure a higher acceptance rate without raising the offer (at least for now). For $ACLX holders, the low tender rate keeps the deal in a bit of a “wait-and-see” zone. If participation stays low, expect: Continued deal pressure Possible negotiation dynamics Increased volatility into the deadline
0 · Reply
DonCorleone77
DonCorleone77 Apr. 1 at 8:16 PM
$ACLX $GILD Gilead extends tender offer to acquire Arcellx Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
0 · Reply
SBroomy
SBroomy Mar. 19 at 2:06 PM
$ACLX $SPY Unfazed by whatever is going on in the market
0 · Reply
Innovatenow
Innovatenow Mar. 7 at 5:11 AM
$ACLX https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-is-investigating-the-mergeraclx-vre-ehab-and-ceco-302704159.html
0 · Reply
Mergerbrief
Mergerbrief Mar. 6 at 12:38 PM
$ACLX / $GILD – Tender Offer File By date
0 · Reply
SBroomy
SBroomy Mar. 5 at 6:36 PM
$ACLX $SPY Arcellx have hold up very well since it's gains.
0 · Reply
Achandler787
Achandler787 Mar. 5 at 3:56 AM
$ACLX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 6:59 PM
$ACLX RSI: 85.61, MACD: 11.9080 Vol: 21.44, MA20: 81.95, MA50: 72.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 27 at 2:20 AM
$ACLX congrats longs! $GILD should buy $ALT or $IMRX next 🚀
0 · Reply
IN0V8
IN0V8 Feb. 25 at 6:46 PM
$ACLX 2/24 Citigroup cuts to neutral from buy Citigroup raises target price to $115 from from $110 Leerink Partners cuts to market perform rating Leerink Partners raises target price to $115 from $109 Stifel cuts to hold from buy; cuts target price to $115 from $127 Truist Securities cuts to hold from buy; cuts PT to $120 from $134 UBS cuts to neutral from buy UBS raises target price to $115 from $100 Wells Fargo cuts to equal weight from overweight Wells Fargo raises target price to $115 from $100
0 · Reply
Parobull
Parobull Feb. 25 at 4:41 PM
$HCWC is wildly undervalued. 30M in profits, cash flow positive, heavy shorts, and almost no borrow left. That’s squeeze fuel. Gap sitting in the .50s once it flips, this could move fast. $ATER $ACLX $AIB $ALUR
1 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 7:17 PM
$GILD to acquire $ACLX for $115 per share in cash plus a $5 CVR, totaling $7.8B — strengthening its position in cell therapy 🚀 Gilead's strategic acquisition aims to streamline control over anito-cel therapy, enhancing its cell therapy position via Kite Pharma. ACLX shares soared 77.43% on the news. Discover the full implications here 👉 https://www.zacks.com/stock/news/2874572/gild-to-acquire-aclx-for-78b-gain-full-control-of-anito-cel?cid=sm-stocktwits-2-2874572-body-34988&ADID=SYND_STOCKTWITS_TWEET_2_2874572_BODY_34988
0 · Reply
IN0V8
IN0V8 Feb. 24 at 4:06 PM
$ACLX 2/23 Baird raises target price to $115 from $106 Piper Sandler cuts to neutral from overweight
0 · Reply
erevnon
erevnon Feb. 24 at 2:23 PM
Citigroup downgrades Arcellx $ACLX from Buy to Neutral and raises the price target from $110 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Feb. 24 at 2:10 PM
Stifel downgrades Arcellx $ACLX from Buy to Hold and lowers the price target from $127 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Joby099
Joby099 Feb. 24 at 10:41 AM
$VNDA $ACLX $GETY $EHAB
0 · Reply
RunnerSignals
RunnerSignals Feb. 24 at 4:39 AM
Late night market recap $NVO $ACLX $VRE $IBM $SNOW all saw big swings today from trial news to acquisitions and AI fears. see what is driving the action https://stocksrunner.com/news/2026-02-23-late-night-market-recap
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 24 at 4:25 AM
$ACLX Massive volume spike on Feb 23 with 32.9M shares traded, way above the 859,408 average volume. Price surged from $64.11 to $113.75. Smart move to wait for a lower H% before considering an entry.
0 · Reply
Lanuchbox
Lanuchbox Feb. 24 at 1:08 AM
$ACLX Check it out https://youtu.be/RD7gwRIEEJk?si=o63xc_6iI9XHBhdX
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 24 at 12:03 AM
Comparing trending tickers $ACLX vs $VKTX: ACLX has surged 77.43% to $113.75 with a trading volume of 32.9M shares, significantly above its average of 859.4K. In comparison, VKTX saw a more modest increase of 11.05% to $34.46 on a volume of 5.7M, slightly above its average of 4.4M. While both stocks are experiencing heightened activity, ACLX is displaying markedly stronger price momentum in relation to its usual trading volume.
0 · Reply
CASTMONEY
CASTMONEY Feb. 23 at 11:45 PM
$EZRA $ACLX I SMELL MONEY ALL OVER $$$$$
0 · Reply